Aston Martin, EasyJet, and Ithaca Energy have been identified among the companies most likely to see significant FTSE index movement in the near term. Index reshuffles can have an outsized effect on
MoreRayzeBio, a Bristol Myers Squibb company, plans to invest more than $173 million in central Indiana operations and build a major new manufacturing facility. The company will establish an approximately 450,000-square-foot facility
MoreExxonMobil remains one of the most closely watched names in the global energy sector, with investors tracking its performance against diversified upstream exploration and production peers. The upstream exploration and production segment
MoreHeidi Overton, currently serving as deputy director of domestic policy at the White House, is reportedly in line to become the next FDA commissioner. President Trump is expected to put forward Overton’s
MoreTrellis, a legal research company specialising in U.S. state trial court data, has significantly expanded its artificial intelligence capabilities across multiple platforms. The company has launched a new plugin for OpenAI’s ChatGPT
MoreThe growing wave of copyright litigation against artificial intelligence developers is raising serious concerns about the long-term accessibility of AI tools for businesses and consumers. Lawsuits filed by authors, publishers, visual artists,
MoreSnapchat has unveiled a new advertising format designed specifically for pharmaceutical marketers, making it easier to include required product disclosures within in-feed ads. The updated format allows pharma advertisers to attach product
MoreNuclear energy stocks have attracted growing investor interest as the surge in artificial intelligence infrastructure creates enormous new demand for reliable, low-carbon electricity. Data centres powering AI workloads require vast and uninterrupted
MoreAlembic Pharmaceuticals has received a formal warning letter from the U.S. Food and Drug Administration targeting its bioequivalence research facility in Vadodara, India. The warning letter, dated July 10, 2026, follows an
MoreSkadden Arps faces mounting political pressure over its conflict of interest concerns tied to its deal with the Trump administration and its simultaneous legal work for Intel. Senators Richard Blumenthal and Adam
More
